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1  | INTRODUC TION
The immune system of an organism is charged with protecting the 
host against pathogenic microbes, but this response must be ap-
propriate and measured. It is increasingly clear that inappropriately 
calibrated responses are pathologic, where insufficient responses 
may enable an infection to spread quickly and overly aggressive 
responses may clear the pathogen but result in severe incidental 
tissue damage. A successful host immune response is generally the 
result of both pro- and anti- inflammatory elements that are carefully 
tuned with the goal of clearing the pathogen and limiting host dam-
age. Our focus here is on persistent infections, where we often think 
of the immune response as being “balanced” between pro- and anti- 
inflammatory responses that produce steady- state outcomes that 
are acceptable to both host and pathogen—enabling both to survive 
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Abstract
Immune responses to pathogens are complex and not well understood in many dis-
eases, and this is especially true for infections by persistent pathogens. One mecha-
nism that allows for long- term control of infection while also preventing an 
over- zealous inflammatory response from causing extensive tissue damage is for the 
immune system to balance pro- and anti- inflammatory cells and signals. This balance 
is dynamic and the immune system responds to cues from both host and pathogen, 
maintaining a steady state across multiple scales through continuous feedback. 
Identifying the signals, cells, cytokines, and other immune response factors that me-
diate this balance over time has been difficult using traditional research strategies. 
Computational modeling studies based on data from traditional systems can identify 
how this balance contributes to immunity. Here we provide evidence from both ex-
perimental and mathematical/computational studies to support the concept of a dy-
namic balance operating during persistent and other infection scenarios. We focus 
mainly on tuberculosis, currently the leading cause of death due to infectious disease 
in the world, and also provide evidence for other infections. A better understanding 
of the dynamically balanced immune response can help shape treatment strategies 
that utilize both drugs and host- directed therapies.
K E Y W O R D S
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long- term. The balance is dynamic as it requires (and responds to) 
continuous feedback from both pathogen and host and might be 
achieved in multiple ways: between pro- and anti- inflammatory 
cytokines and cells at the molecular, organ, and whole- host levels; 
between isolating and engaging the pathogen; and over space and 
time. This balance is not necessarily quantitative (eg, equal concen-
trations of pro- and anti- inflammatory cytokines), but it is a quali-
tative harmonization in downstream activation and inhibition. Our 
primary example here will be tuberculosis (TB), but these principles 
also apply to other persistent diseases such as Helicobacter pylori 
infection and Hepatitis C (HCV) and to acute scenarios like sepsis. 
In this review, we provide evidence that a dynamic balance between 
pro- and anti- inflammatory cells and cytokines generated following 
infection results in an optimized trade- off between pathogen clear-
ance and increased pathology. We demonstrate that this balance 
occurs not only spatiotemporally but also at both local and whole- 
host scales.
Figure 1 illustrates conceptual inflammatory response profiles 
over time (Panel A) and their corresponding outcome trajectories 
following infection (Panel B). If the inflammatory response is too 
weak or too slow, the pathogen will replicate freely and the host may 
succumb to infection (outcome i). If the inflammatory response is too 
strong, the pathogen may be eliminated, but at the price of excessive 
inflammatory damage to host tissue (outcome ii). In some cases, the 
immune system may mount a large inflammatory response, but the 
pathogen is too robust to be properly contained (outcome iii). The 
other 2 trajectories are examples where a pathogen is either con-
tained or eliminated. In one case, the immune system does its job 
properly, mounting an appropriate inflammatory response that elim-
inates a pathogen while simultaneously decreasing inflammation via 
an effective and appropriate anti- inflammatory response (outcome 
iv). The other scenario is persistent infection, where the immune sys-
tem and pathogen reach a stalemate, or steady state. The immune 
system produces a level of mild inflammation, and total pathogen 
burden eventually reaches a level where it does not significantly in-
crease or decrease over time (outcome v). The trajectory of a given 
infection arises from the complex dynamics of the interaction be-
tween host and pathogen.
2  | PRO - AND ANTI-  INFL AMMATORY 
MEDIATORS RELE VANT TO PERSISTENT 
DISE A SES INCLUDE BOTH CELL S AND 
MOLECULES
The role of cells trafficking between sites of infection and the drain-
ing lymph nodes (LN) is crucial in immune dynamics. Lymphocytes 
work individually and coordinate with each other to perform their 
immune functions. Specific immune cells, such as macrophages and 
some CD4+ T cells, secrete pro- inflammatory signals (IFN- γ, TNF, 
F IGURE  1 Dynamics of pro- and anti- inflammatory immune responses steer disease progression along various trajectories. Schematic 
of relative pro- and anti- inflammatory responses to a pathogen over time corresponding to various host outcomes (A). Schematic of disease 
trajectories corresponding to qualitative ratios of pro- and anti- inflammatory responses (B). The outcomes are (i) high pathogen burden 
(blue); (ii) severe tissue damage (red); (iii) high pathogen burden along with a large amount of tissue damage (gray); (iv) a cleared infection and 
return to base levels of inflammation (white); (v) a dynamically balanced pro- and anti- inflammatory response to control pathogen growth 
and limit host pathology (purple)
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etc.) and perform inflammatory functions. Cytotoxic CD8+ T cells 
and activated macrophages kill pathogens and infected host cells ei-
ther directly or by induction of cell apoptosis.1-3 In contrast, other 
cell types, such as regulatory T cells, serve to suppress or shut down 
the immune response via cell- cell contact and cytokine secretion.
Pro- inflammatory cytokines, including chemokines, are signal-
ing molecules that are secreted from immune cells, such as T cells 
and macrophages, and other cells that promote inflammation and 
immunity. Some of the most studied pro- inflammatory cytokines 
include interleukin- 1 (IL- 1), IL- 12, tumor necrosis factor alpha (TNF), 
interferon gamma (IFN- γ), and granulocyte- macrophage colony 
stimulating factor (G- MCSF). (For a more comprehensive list see4,5). 
Pro- inflammatory cytokines are predominantly produced by and 
involved in the upregulation of immune responses, including acti-
vation of macrophages, induction of apoptosis, and recruitment of 
additional immune cells. In contrast, anti- inflammatory cytokines se-
creted from immune cells, such as regulatory T cells and some mac-
rophages, serve to suppress inflammation and immunity. The list of 
anti- inflammatory cytokines is also large, but the primary ones that 
we focus on here include IL- 4, IL- 10, and transforming growth factor 
beta (TGF- β).4,5
In order to achieve pathogen control without inducing excessive 
inflammation and tissue damage, an appropriate and dynamic bal-
ance between pro- and anti- inflammatory mediators must exist and 
evolve over time. Here, we review both experimental and mathe-
matical/computational studies that support the concept of an im-
mune balance during persistent infections. Experimental studies are 
critical to uncovering the identities of pro- and anti- inflammatory 
players in the immune response and identifying the consequences 
of disrupting balance. Mathematical and computational studies can 
be used to generate understanding, test hypotheses, fill in gaps, and 
make predictions. The ultimate goal is to harness knowledge and 
isolate factors influencing this dynamic balance to provide strate-
gies for better patient outcomes. For example, analysis of models 
can identify immunomodulatory factors that, combined with anti-
biotics, enable patients to achieve pathogen clearance. We demon-
strate that the type of balance required for controlling a pathogen 
and limiting host damage differs among different diseases and over 
spatiotemporal scales.
3  | MYCOBAC TERIUM TUB ERCULOSIS  
INFEC TION
TB is a deadly infectious disease caused by the bacterium M. tuberculo-
sis (Mtb). Figure 2 outlines the multi- scale and multi- organ interactions 
occurring during infection. Briefly, infection occurs after Mtb inhala-
tion into the lungs, where it is taken up by resident antigen- presenting 
F IGURE  2 Multi- organ events 
following infection with Mycobacterium 
tuberculosis. Mtb is inhaled into 
lungs and engulfed by macrophages 
where intracellular replication occurs. 
Additionally, DCs take up Mtb and 
traffic to lung- draining LNs via afferent 
lymphatics, where they prime T cells that 
have been recruited from high endothelial 
venules (HEV). These primed T cells 
migrate to lungs via efferent lymphatics 
and participate in granuloma formation 
and function by activating macrophages, 
secreting cytokines, and participating in 
adaptive immune responses
150  |     CICCHESE Et al.
cells (APCs), such as macrophages and DCs that initiate granuloma for-
mation. Granulomas are organized cellular structures comprised pri-
marily of lymphocytes, neutrophils, and macrophages, with or without 
centralized caseous necrosis and are the pathologic hallmark of TB.6-8 
Humans experience either latent tuberculosis infection (LTBI)—a sub-
clinical but long- term, persistent Mtb infection (about 90% of cases), 
or active primary disease (about 10% of cases).7,9,10 Protection against 
TB can be defined as host responses that prevent development of ac-
tive disease, or in other words, long- term controlled infection (clinically 
latent).11 A human with LTBI likely retains relatively small numbers of 
Mtb within granulomas in lungs or LN granulomas, does not have any 
symptoms of disease, and is not contagious, but has a 10% lifetime risk 
of reactivation to active TB.12 Compromising the immune system by 
pharmacologic manipulation of TNF or HIV infection substantially in-
creases the risk of reactivation, emphasizing that immunity maintains 
control over clinically latent infection.13,14
Granulomas are organized immune structures, and while gran-
uloma microenvironments promote control of infection, they also 
provide an intra- host niche for bacterial survival. Studies on Mtb- 
infected humans and non- human primates (NHPs) demonstrate 
that an individual may contain a spectrum of granuloma types (eg, 
solid cellular, caseous- necrotic, and disseminating), each with dif-
ferent bacterial loads.15-19 The mechanisms driving protection and 
pathology at the individual granuloma level are poorly understood 
but are likely to be important for determining whether Mtb infection 
progresses to active or latent disease at the organism scale.6,17,20 
Furthermore, identifying these mechanisms may lead to advances 
in treatment and host- directed therapies that shift the balance of 
protection and pathology to the host’s favor.
4  | E XPERIMENTAL SUPPORT FOR A 
BAL ANCED RESPONSE IN TB
There is substantial evidence that both pro- and anti- inflammatory 
elements are present in the immune response to Mtb infection, and 
that both play essential roles.21 A pro- inflammatory TH1 response 
driven by CD4+ T cells producing IL- 2, IFN- γ, and TNF is essential 
for controlling Mtb infection.22-27 CD4+ and CD8+ T cells produce 
cytokines that activate other immune cells, including activation of 
macrophages that can kill Mtb,1,28 and cytotoxic CD8+ T cells that 
can kill Mtb- infected macrophages.29-31 Most Mtb- infected people, 
including people with active TB, have Mtb- specific TH1 responses 
suggesting TH1 responses are necessary, but not sufficient, factors 
in infection control. T cells are necessary to control Mtb infection, as 
mice or NHP without CD4+ or CD8+ T cells progress rapidly to ac-
tive TB.28,31-35 HIV or SIV co- infection, which depletes CD4+ T cells, 
greatly increases risk of active TB in patients and macaques.13,36,37
Anti- inflammatory responses are important for preventing ex-
cessive lung pathology during Mtb infection.38-43 Macrophages in-
fluence inflammation in TB44 and can be divided into subsets based 
on activation status (M1 or classically activated macrophages–
CAM–and M2 or alternatively activated macrophages–AAM).45-49 
Anti- inflammatory cytokines produced in granulomas, such as IL- 27, 
IL- 10, and TGF- β, can act on T cells. Other cells that participate in 
anti- inflammatory responses to Mtb include TH17 cells,50-53 regu-
latory T cells (Tregs, CD4+Foxp3+ T cells),54-56 and neutrophils.57,58 
There are limited data on the role of these cell subsets in Mtb in-
fection. In mice, TH17 cells are important in optimizing vaccination 
against TB59-62 by enhancing induction or recruitment of TH1 cells 
to lungs. Tregs modulate immune responses by inhibiting prolifer-
ation and cytokine production by T cells, through production of 
IL- 10 or TGF- β, or direct contact. In mice, Tregs inhibit control of 
Mtb by downregulating T- cell responses.63,64 One recent study in 
NHPs supports that balanced pro- and anti- inflammatory responses 
are associated with some sterilized granulomas; meaning that the 
ability of granulomas to clear bacteria on a per granuloma basis is 
based on the presence of both pro- and anti- inflammatory media-
tors, which correlates with good outcomes.42
Some T cells (at least at some point in their lifecycle) have been 
identified as producing multiple cytokines simultaneously. The 
presence of these so- called multifunctional T cells (MFTs) has been 
shown to correlate with a protective response in some diseases, 
while there is evidence that MFTs can act to increase pathology and 
inflammation in others.65-72 The role of MFTs in TB remains poorly 
characterized. There is conflicting evidence as to whether the pres-
ence of MFTs confers protection, with most human TB studies fo-
cusing on T cells derived from the periphery where the frequency of 
MFTs is often, although not always, associated with active disease 
rather than protection.73,74 A study by Qiu et al75 found that the per-
centage of MFTs in TB is significantly higher in active TB cases than 
in those with clinically latent TB or compared to healthy controls. 
Conversely, it has also been reported that active TB patients have 
increased numbers of single positive, TNF- secreting T cells and less 
MFT cells than those with clinically latent TB.76 Elevated numbers of 
MFTs have been observed following TB vaccination.77 At the gran-
uloma level, a study recently showed that the majority of T cells in 
NHP TB infection secrete a single cytokine, but that there is a subset 
of T cells that secrete up to 5 pro- inflammatory cytokines concur-
rently. In addition, a small subset of cells secreting both pro- and anti- 
inflammatory cytokines, namely IL- 17 and IL- 10, were also observed, 
suggesting that a dynamic balance can be executed even at a single- 
cell level.42 While there are still limited data available to determine 
what role MFTs play in controlling infection and limiting pathology in 
TB and other diseases, the fact that MFTs are able to secrete either 
or both pro- and anti- inflammatory cytokines throughout disease es-
tablishes them as players in achieving and maintaining balance.
5 | MATHEMATICAL AND COMPUTATIONAL 
MODELING STUDIES AT THE WHOLE LUNG 
LEVEL SUPPORT A BALANCE OF PRO- AND ANTI- 
INFLAMMATORY FACTORS IN TB
Models of the immune mediators have furthered our understanding 
of immune responses and also of viral infection (see this special issue 
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and also cf.78-82), and such models have proved particularly insightful 
for TB.83 Model development can be specific to molecular, organ, 
host, or population scales, or can involve combining different- scale 
models (eg, using a multi- scale approach); multi- scale models can be 
particularly valuable to further understanding of the processes ac-
tive in disease development as they account for molecular and cel-
lular dynamics operating over time as well as physiological scales, 
ranging from molecular to organ to the entire host.83
Early modeling studies of pro- and anti- inflammatory factors in 
TB were focused on the whole lung as data available were derived 
from studies on whole lungs of infected animals. Wigginton and 
Kirschner84 highlighted the importance of maintaining a balance of 
concentrations of pro- and anti- inflammatory cytokines across time 
within the lung during TB infection. The data used to calibrate the 
model were derived from what was then the only known measure-
ment from humans in vivo, broncho- alveolar lavage fluid, as blood 
data do not provide local infection information. Ordinary differential 
equations (ODEs) track whole lung dynamics of cells, cytokines, and 
bacteria. More specifically, the model tracks the temporal dynamics 
of macrophages, divided into resting, activated, and infected states; 
T lymphocytes, including individual populations of activated CD4+ 
naive T cells and the type 1 helper and type 2 helper they differenti-
ate into (CD8+ T cells were not directly included, but their cytotoxic 
effects were accounted for indirectly); as well as concentrations of 
IFN- γ, and IL- 4, IL- 10, and IL- 12. To assess the impact of levels of 
pro- and anti- inflammatory cytokines, the authors vary sources of 
cytokines as well as production and decay rates. In addition, virtual 
deletion and depletion experiments were simulated. In a framework 
with an increased anti- inflammatory or decreased pro- inflammatory 
response, the system moves to active infection. In a framework 
with an increased pro- inflammatory or decreased anti- inflammatory 
response, the system increases the ability to control infection but 
also increases damage to tissue (Figure 1). Results from this study 
suggest that a dynamic balance must be struck between pro- and 
anti- inflammatory cytokines in order to suppress bacterial infec-
tion in the most efficient way possible and thereby minimize tissue 
damage. In addition, while mouse studies suggested that there was 
no phenotype to an IL- 10 knockout mouse,85 this model predicted 
that IL- 10 plays a key role in stabilizing immune response dynamics. 
This supports the idea that both pro- and anti- inflammatory signals 
trade- off dynamically during infection to produce an optimized, con-
trolled response that limits bacterial load without inducing signifi-
cant damage.
6  | MACROPHAGE POL ARIZ ATION AND 
ITS ROLE IN BAL ANCE
This idea of balance is explored further in next- generation models 
that track additional relevant immune cell types (including DCs, 
cytotoxic T cells, and macrophages of specific phenotype), and in-
vestigate multi- organ dynamics of cell trafficking, antigen presenta-
tion, and cell priming occurring between the lung and lung- draining 
LNs.86–92 One goal of these studies is to focus on the role of cy-
tokines on the interplay between the spectrum of phagocytic popu-
lations (macrophages and DCs) and inflammation. The idea is to 
identify control mechanisms for immune protection by dissecting 
the effects of pro- inflammatory (eg, TNF) and anti- inflammatory (eg, 
IL- 10) cytokines in lung and LN environments. It is not clear how this 
balance translates into macrophage polarization and their plasticity, 
or how the relative contribution of these macrophages, broadly clas-
sified as M1 (or classically activated macrophages- CAM) and M2 (or 
alternatively activated macrophages- AAM), evolves over time and 
leads to an effective immune response, at the scale of a granuloma.
The mathematical representation used in these studies is a 
multi- compartmental model including separate systems of ODEs 
representing lungs84 and is linked to ODE models of LN and blood. 
The model is calibrated to datasets from murine samples over mul-
tiple time points.86,87,90 Based on a study by Day et al93, the model 
describes 4 different macrophage subpopulations, both in lung and 
LN: uncommitted/resting/resident (M0), infected (MI), classically ac-
tivated (M1, also denoted MA), and alternatively activated (M2).
89–91 
A pool of macrophages that reside in the blood (as monocytes) and 
cells are continuously recruited to the lung based on danger signals 
and inflammatory chemokine/cytokine gradients.94 Macrophage 
polarization is defined as a function of IFN- γ (pro), TNF (pro), IL- 10 
(anti), and bacteria (both) that collectively drive macrophage differ-
entiation into either an M1 or M2 phenotype.89
The model defines the concept of switching time93 as the 
time needed to switch from an AAM- dominated (M2) to a CAM- 
dominated (M1) lung environment during Mtb infection. Studies 
found that switching time is negatively affected by higher IL- 10 
saturation thresholds: more IL- 10 is needed to skew macrophage 
populations to an AAM phenotype. The biological relevance of in-
creasing a switching time (on the order of days) is that a delay in CAM 
presence and pro- inflammatory cues in lung may be responsible for 
Mtb gaining an initial foothold. The concept of a switching time also 
supports the hypothesis of a dynamic balance between pro- and 
anti- inflammatory cues that can shape infection progression and ul-
timately affect the outcome.89
7  | COMPUTATIONAL MODEL OF 
GR ANULOMA FORMATION AND FUNC TION
As described above, Mtb infection largely plays out at the level of 
individual granulomas. Some granulomas may sterilize (clear all bac-
teria), but clinically latent TB is the result of 1 or more granulomas 
which contain, but do not eliminate, the pathogen.18 Granulomas 
evolve largely independently from one another,95 and thus it is likely 
that a balance of pro- and anti- inflammatory factors are responsible 
for the outcome of infection at an individual granuloma level. The 
structure of a granuloma—a characteristic cuff of lymphocytes sur-
rounding an inner core of macrophages, in humans and NHPs—likely 
plays an important role in infection progression and in treatment. 
Granulomas are difficult to study, and generally can be examined in 
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detail only at necropsy in animal studies. However, recently obtained 
PET/CT imaging data from individual NHP granulomas can report 
granuloma size and metabolic activity at multiple time points prior 
to necropsy.95,96
Use of computational models of single granulomas can generate 
insights into how the structures form and how a balance of pro- and 
anti- inflammatory factors may play out in the evolution of the infec-
tion at the single granuloma level. Importantly, these models account 
for changes in cellular and molecular concentrations in both space 
and time. This versatility allows for exploration of the role of dy-
namic balance of pro- and anti- inflammatory mediators in infection 
outcomes at both single granuloma and collective scales.
GranSim is a hybrid computational model that integrates agent- 
based, ODE, and PDE models. It captures the formation and be-
havior of a granuloma is calibrated to biological data and has been 
continuously curated since 2004.97–101 Segovia- Juarez et al created 
the first iteration of GranSim as an agent- based model (ABM) that 
describes cellular behavior, including recruitment, changes of state 
(activation, infection, etc.), and movement during granuloma forma-
tion. Subsequent iterations contain macrophages (M1 and M2) and 
T cells (CD4+, CD8+, and Tregs) as agents that can have multiple 
states and phenotypes (eg, infected, activated, etc.),89 and bacte-
ria represented as either continuous functions or as agents in the 
extra- or intracellular environment.102 Probabilistic interactions 
between immune cells and bacterial populations are described by 
a well- defined set of rules that are continually updated with new 
biological datasets.
The diffusion of relevant chemokines, cytokines, and other sol-
uble ligands is determined by solving partial differential equations. 
GranSim can capture receptor- ligand binding and intracellular signal-
ing events of cytokines, such as TNF or IL- 10, either with ODEs that 
are solved within each agent or a linear model.97,98,101,103 The precise 
model used is determined by the questions being asked. Using an 
approach termed “tunable resolution”, model resolution can toggle 
between fine- grained (more detailed) and coarse- grained (less de-
tailed) as needed, based on the biological events described.104
In GranSim, information is continually exchanged across scales in a 
computationally efficient manner, incorporating molecular and cellu-
lar events explicitly with tissue- scale behavior (granuloma formation) 
as an emergent feature of the model. Rules and typical parameters 
for GranSim are available online at http://malthus.micro.med.umich.
edu/GranSim. Simulations are representative of a 4 mm2 or 16 mm2 
FIGURE  3 Computational and experimental visualizations of various granulomas. A zoomed in 2- D GranSim snapshot (A), which shows 
macrophage substates (green- resting, blue- activated, orange- infected, red- chronically infected), T- cell phenotypes (pink IFN- producing, purple- 
cytotoxic, light blue- Tregs), extracellular bacteria (yellow), necrosis (white). (B) is a GranSim snapshot of a different granuloma that shows the 
concentration gradient of TNF (units on colorbar are molecules of TNF per grid compartment). (C) is a macaque granuloma image stained for 
macrophages (Red CD68), T cells (Green CD3), and neutrophils (Blue calprotectin). (D) is a time plot of CFU/lesion NHP data (red, median with 
error bars indicating min/max) along with GranSim simulations with model predictions (median—solid line, min/max—dashed lines). Simulations 
plotted as in 103 with a newer generation of GranSim and data derived from 32 NHP in previously published works 6,17,95,212,213
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cross- section of lung tissue (Figure 3A). Each simulation follows 
events over several 100 days, building over time to track thousands 
of individual cells (agents). One strength of this approach is that gen-
erated in silico data can be tracked in both space and time. Marino 
et al88 have generated an in silico library of tens of thousands of vir-
tual granulomas that can be used as a virtual repository for repeated 
study. The model can also track temporal and spatial gradients of 
molecular concentrations on the grid (Figure 3B). These virtual gran-
ulomas can be validated experimentally by comparing with spatial 
images generated using immunohistochemistry and imaging derived 
from both human and NHP granulomas (Figure 3C). GranSim is able 
to recapitulate these spatial dynamics, and also temporal dynamics, 
such as fitting to NHP data on colony- forming units (CFU) (Figure 3D).
8 | COORDINATED ROLES FOR IL- 10, TNF, AND 
TGF- β IN SPATIOTEMPORAL DYNAMICS OF 
GRANULOMA FORMATION AND FUNCTION
GranSim simulations predict that a balance between pro- and 
anti- inflammatory factors is necessary to achieve, at the granu-
loma level, control over Mtb and the immune response (Figure 4). 
Granulomas that favor anti- inflammatory responses fail to control 
bacterial growth, whereas granulomas that favor pro- inflammatory 
responses may sterilize a granuloma, but at the price of increased 
necrosis and caseum. GranSim has been used to explore the indi-
vidual roles of pro- and anti- inflammatory cytokines TGF- β, TNF, 
and IL- 10 and then evaluate their roles in combination to provide 
F IGURE  4 Balanced immune responses lead to contained Mtb granulomas. The top row (A, B, C) displays conceptual images of 
granuloma formation across a spectrum of immune responses. During a primarily anti- inflammatory response (A), a granuloma shows a lack 
of proper formation, and large amounts of caseum develop as the host struggles to contain the pathogen. A balanced response (B) displays 
proper granuloma formation and containment of the pathogen. A primarily pro- inflammatory response (C) clears the pathogen, but at the 
cost of widespread cellular activation, death, and inflammation. The bottom row (D, E, F) displays GranSim simulation snapshots of these 
scenarios at day 150 post infection. A containment simulation from baseline parameter ranges is demonstrated in (E), whereas a simulation 
from a TNF- depletion parameter set is shown in (D), and a simulation from an IL- 10 knockout parameter set that also exhibits more pro- 
inflammatory behavior (F). (D), (E), and (F) correspond to the conceptual immune responses displayed in (A), (B), and (C), respectively
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evidence that a balanced response to these inflammatory cytokines 
is necessary for granuloma formation and maintenance.97,98,105–107
Within a granuloma, the major producers of the pleiotropic cyto-
kine TNF are macrophages, effector T cells, and DCs. TNF has also 
been thought to play a role in the activation of macrophages—stim-
ulating further cytokine or chemokine production as well as initiat-
ing bacterial killing, and inducing macrophage apoptosis.44,99,108–112 
However, without the ability to measure an in vivo gradient of TNF 
or to generally measure TNF activities in vivo, the spatiotemporal dy-
namics of TNF are unable to be analyzed experimentally. Therefore, 
Fallahi- Sichani et al98,106 explored the role of TNF using GranSim, by 
creating a multi- scale molecular to tissue model. The model predicts 
that there is an interplay between molecular events occurring at 
the second to minute timescales and the long- term events of im-
mune response to Mtb. In particular, TNF receptor 1 internalization 
kinetics modulate a diverse set of outcomes. At low receptor inter-
nalization rates, the granuloma sterilizes, but at the cost of excessive 
inflammation. At high internalization rates, the granuloma cannot 
control growth of Mtb. Finally, at internalization rates that match 
experimental values, many in silico granulomas are able to contain 
Mtb growth without excessive inflammation. Studies have shown 
that internalization of TNF acts as a regulator of both paracrine and 
autocrine responses to TNF, influencing activation and apoptosis in 
macrophages.98,106
The models also predict that there exists a TNF gradient within 
a single granuloma, with highest concentrations near the center, and 
that this gradient determines the spatial range of TNF action within 
the granuloma.98 The gradient is controlled by the TNF receptor in-
ternalization dynamics described above. An attempt to detect such 
a TNF gradient is shown in Figure 5C, using immunofluorescence 
F IGURE  5 Cytokine distribution across in silico and bead model granulomas. (A) GranSim snapshot of a representative containment 
granuloma scenario at 50 days post infection. The TNF (red) and IL- 10 (blue) gradients of this representative granuloma are shown in (B). 
In GranSim granulomas, the gradient of TNF is contained within the granuloma (see diameter of granuloma on x- axis), and the gradient 
of IL- 10 spreads along the diameter of the granuloma. This particular set of gradients is representative of containment granulomas and is 
consistent across time. If the spatial range of TNF is too large, bystander cellular death increases despite little increase in bacterial killing. 
If TNF spatial distribution is too narrow, simulations show increased bacterial load. Similarly, if IL- 10 has a spatial distribution that is too 
wide, IL- 10 decreases bystander cell death, but causes increased bacterial loads in the granuloma. Yet, too narrow of an IL- 10 distribution 
yields too powerful of a pro- inflammatory response. (C) The well- established PPD bead model of granuloma formation in mice (protocol in 
106,113–116) can determine whether there is a gradient of soluble TNF within a single granuloma and detect soluble TNF gradients in ex vivo 
granuloma tissue. Immunofluorescence techniques identify the spatial organization of cells in granulomas, and then this known organization 
is combined with flow cytometry data,106 a simple receptor- ligand model, and fluorescent microscopy of unbound TNF receptors to 
reconstruct the relative soluble TNF gradient. A molecular probe from biotinylation of recombinant TNF was constructed to target unbound 
TNF receptors.214–218 In the representative PPD bead granuloma shown, stains are for free TNFR (yellow) using the biotinylated TNF probe 
and cell nuclei (blue) using DAPI. The dashed white circle indicates approximate PPD bead location. Entire image was used. (D) Intensity of 
biotinylated TNF in image from (C) as a function of radial distance from the center of the PPD bead, binned into 25 pixel lengths. Unbound 
TNFR is roughly inversely proportional to gradient of soluble TNF (derived from the simple receptor- ligand model). Bars indicate standard 
deviation 219
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staining on lung cryo- sections from the well- established PPD bead 
model of granuloma formation in mice (protocol in106,113–116). Free 
(unbound) TNF receptor concentrations increase toward the periph-
ery of the granuloma, suggesting a decrease in TNF concentration. 
As the simulations predict (Figure 5B), a contained granuloma in-
cludes a narrow range of TNF activities: as one travels to the pe-
riphery of the granuloma, there is less TNF available to bind to TNF 
receptors.
Simulations with GranSim can also elucidate the role of IL- 
10 within the granuloma at both molecular and cellular scales. 
Decreased levels of IL- 10 lead to a greater likelihood of steriliza-
tion, but at the cost of more caseation and cellular death at earlier 
time points in infection. Bacterial persistence can be achieved by 
increasing levels of IL- 10 produced by infected macrophages. These 
increased levels of IL- 10 allow for a limited immune response during 
early time points of infection and prevent lesion sterilization across 
time.97,103 The role of IL- 10 at early time points supports the impor-
tance of an appropriate cytokine response across time in controlling 
granuloma outcomes.
The dynamics of TGF- β, another anti- inflammatory cytokine, 
can also be examined at both molecular and cellular levels within 
GranSim.107,117–119 These studies present an in silico TGF- β knockout 
and predict an increase in bactericidal activity of cytotoxic T cells, 
thereby decreasing granuloma CFU across time. Furthermore, the 
presence of TGF- β regulates cytotoxic T cell effector function at 
the individual cell level. The individual actions of TGF- β on unique 
cell types within a granuloma indicate that its inhibitory role is less 
straightforward when evaluated within the context of other cyto-
kine actions.
The computational studies reviewed above evaluate the indi-
vidual impacts of TNF, IL- 10, and TGF- β. To evaluate the impact of 
sets of pro- and anti- inflammatory cytokines working in concert, 
Cilfone et al and Warsinske et al performed further sets of in silico 
experiments. They found 2 distinct results. First, Cilfone et al de-
fined a metric of granuloma outcomes, the host- pathogen index, 
which includes factors such as bacterial load, number of activated 
macrophages, and the inverse of the amount of resting macrophage 
apoptosis; lower scores indicate a better outcome for the host. 
Simulations show that an optimal result occurs when the ratio of 
concentrations, [TNF]/[IL- 10], was in a middle range: lower values 
yielded high bacterial loads and higher values lead to excessive in-
flammation.97 In other words, the required balance of pro- and anti- 
inflammatory factors can be determined via simulation.
Additionally, simulations show that both anti- inflammatory me-
diators TGF- β and IL- 10 represent distinct regulatory mechanisms 
within granulomas as each distinctly inhibit effector T cell and mac-
rophage functions, respectively.107 Altogether, the action of each cy-
tokine represents a unique function, but granulomas that effectively 
contain Mtb require that cytokines perform in harmony with other 
cytokines in a dynamic and balanced way.
Importantly, in silico experiments also emphasize the impor-
tance of cytokine spatial dynamics. Figure 5B shows the IL- 10 and 
TNF gradients in a representative contained granuloma at day 50; 
these gradients lead to a granuloma that contains bacteria with-
out the cost of high inflammation and bystander cellular death. 
Immunohistochemical analysis of necrotic NHP granulomas further 
supports a key role for anti- inflammatory cytokines.107
Simulations predict that proper control of Mtb requires a multi- 
scale balance of pro- and anti- inflammatory factors both spatially 
and temporally. This was further supported in later studies with ex-
perimental collaborators.39,42,49 While studies have explored the dy-
namic balance for the case of TNF, IL- 10, and TGF- β,97,98,105–107 this 
concept of balance likely extends beyond these cytokines to include 
other pro- and anti- inflammatory molecules and cell types.
9  | NEUTROPHIL S CONTRIBUTE 
TO BAL ANCING PRO - AND ANTI- 
INFL AMMATORY FAC TORS IN TB
Although the role of neutrophils in the granuloma response to 
Mtb infection remains largely unknown, neutrophils are thought 
to dually influence the protective host immune response and the 
ability to balance inflammatory responses. During Mtb infection, 
neutrophils secrete both pro- and anti- inflammatory cytokines. 
TNF, CCL2, CCL3, CCL4, CCL19, CCL20, CXCL2, CXCL9/MIG, 
S100A8, S100A9, all secreted by neutrophils, recruit monocytes 
and T lymphocytes to the infection site.49,120,121 Notably, the 
majority of the cytokines and chemokines that neutrophils se-
crete in turn function as neutrophil activators or attractants, 
resulting in a positive feedback loop.121 This self- accumulation 
can become detrimental if left unchecked, contributing to im-
mune hyper- reactivity121; namely, although neutrophils do not 
secrete large quantities of pro- inflammatory cytokines at the 
single- cell level, the accumulated amount that a local popula-
tion of neutrophils secretes can become harmful to the host. 
That neutrophil death occurs through the necrosis pathway 
during Mtb, rather than by the anti- inflammatory efferocyto-
sis, and that neutrophil secretion of the anti- inflammatory cy-
tokines IL- 10, IL- 4, and IL- 13 is reduced, both imply that there 
is a positive- feedforward neutrophilic, inflammatory response 
during Mtb.121–123 Through disrupting pro- inflammatory balance 
checkpoints in this way, infections like Mtb are thought to expe-
rience increased pathology.
Easily activated, short- lived, and unable to be depleted in cy-
nomolgus macaque models,6,49,124,125 neutrophils pose unique ex-
perimental challenges to wet lab study. The inherent difficulties of 
experimental work highlight the need for computational modeling, 
as computational models of the immune response to Mtb infection 
enable testing of neutrophil- centric hypotheses that are difficult, 
impossible, or too costly to test experimentally. The value of com-
putational studies in gaining a better understanding of whether 
Mtb disrupts the ability of neutrophils to modulate their secretion 
of pro- and anti- inflammatory cytokines thus cannot be overstated. 
Bru and Cardona126 similarly motivate the importance of using a sys-
tems biology approach to study early granuloma formation, and they 
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present a computational model that builds on the techniques pre-
sented in Kirschner et al.100 This model is noteworthy in the context 
of this review as it both includes neutrophils—although allows them 
limited abilities, eg, only macrophages are able to secrete chemok-
ines—and emphasizes the importance of temporal chemokine distri-
bution and concentrations in the progression of Mtb pathology.126 It 
also suggests a link between persistent, spatially dependent chemo-
kine secretion and effective granuloma formation, and exemplifies 
how mathematical models can help us to better understand early 
inflammatory responses. While further work is needed both exper-
imentally and computationally to elaborate the role of neutrophils 
in Mtb infection at the granuloma scale, it is clear that their role in 
maintaining a dynamic balance will be key.
10  | MODUL ATING THE DYNAMIC 
INFL AMMATORY BAL ANCE FOR TB 
THER APY
Standard TB therapy consists of 6 months or longer of multiple an-
tibiotics. There are many factors that cause patients to fail to ad-
here and complete this lengthy treatment.127 Shortening TB therapy 
could help increase the number of patients that complete treatment, 
as well as increase efficacy, but it can be difficult to predict regimen 
efficacy in humans. Rationalizing new therapy approaches requires 
an understanding of exposure levels of therapeutic agents within the 
granuloma, as well as consideration of how therapies can modulate 
the inflammatory balance that occurs within a granuloma to control 
TB.
We have argued that the organization and formation of the 
granuloma require a dynamic balance of pro- and anti- inflammatory 
responses. Successful granulomas (ie, those that control bacterial 
levels or sterilize them completely) can help contain infection and 
prevent Mtb from infecting healthy lung tissue.8 Although this may 
be considered a positive alternative to active TB, there is strong 
evidence that granulomas also act as a physical and physiological 
barrier to antibiotic diffusion.128,129 Imaging techniques, such as 
matrix- assisted laser desorption/ionization coupled with mass spec-
trometry (MALDI- MS) allow for semi- quantitative analysis of anti-
biotic distribution in granuloma tissue samples and can show that 
many antibiotics fail to evenly distribute throughout granuloma le-
sions and often accumulate outside of caseous regions.130 This may 
explain the lack of clinical success of some antibiotics that show 
promise in preclinical trials.
There is a close relationship between granuloma structure 
and antibiotic distribution. Because granuloma formation and 
structure both depend on the dynamic balance of pro- and 
anti- inflammatory signals, generating models to predict anti-
biotic efficacy for Mtb requires modeling both immune system 
phenomena and pharmacokinetics. To this end, Pienaar et al131 
added pharmacokinetic and pharmacodynamic (PK and PD) 
models into GranSim to study how different antibiotics distrib-
ute within granulomas and contribute to sterilization. The PK 
model includes a compartmental, ODE plasma PK model that 
captures absorption into plasma following an oral dose, ex-
change with peripheral tissue, and metabolic clearance of the 
antibiotic. The agent- based simulation references the plasma 
PK model to deliver antibiotic onto the spatial grid through vas-
cular sources based on local concentration gradients. Solving 
for spatial antibiotic concentration involves modeling diffusion 
through the grid, partitioning into macrophages, and metabolic 
degradation of the antibiotics. The pharmacodynamic model 
incorporates antibiotic- induced bacterial death by determining 
antibiotic killing rate constants or probabilities based on Hill 
curve kinetics.
To incorporate granuloma heterogeneity while simulating an-
tibiotic therapy, parameters that control host immune responses 
can be varied. Many of these parameters modulate the balance of 
the pro- and anti- inflammatory cytokine responses, as well as cap-
ture sensitivity of immune cells to these signals, such as thresholds 
for immune cell activation and cellular recruitment. The combined 
model reveals how the balanced inflammatory response and gran-
uloma formation affect antibiotic distribution and efficacy. Figure 6 
shows isoniazid concentration 2 hours following an oral dose in 3 
F IGURE  6 Simulated antibiotic distributions in granulomas using GranSim. Heat maps of isoniazid (INH) concentration for the 3 
representative granulomas shown in Figure 4: one that is highly anti- inflammatory (A), one that is contained (B), and one that is highly pro- 
inflammatory (C). Each type of granuloma has lower concentrations of antibiotic compared to the surrounding tissue. The heat maps show 
INH concentration in granulomas after 150 days of infection and 2 hours after a single, oral dose of 5 mg/kg. PK/PD modeled as in131,220
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examples of simulated granulomas: one more anti- inflammatory 
(Figure 4A), one more pro- inflammatory (Figure 4C), and one that is 
balanced (Figure 4B). Within each simulated granuloma, exposure to 
drugs is much lower than exposure outside, indicating that isonia-
zid is prevented from penetrating granulomas that develop under 
inflammatory conditions across the pro- to anti- inflammatory spec-
trum. Although isoniazid penetration is limited regardless of the in-
flammatory balance of a granuloma, an additional feature for why 
granulomas have low antibiotic exposure is the presence of caseum, 
which is an avascular region at the center of granulomas due to the 
build- up of dead cell debris. Analysis of host immune features such 
as sensitivity to TNF- induced apoptosis, macrophage activation, and 
amount of caseation each influence treatment outcome.131 In partic-
ular, increased caseum formation as a result of increased sensitivity 
to a pro- inflammatory response negatively impacts antibiotic pene-
tration and treatment outcome.
In an effort to characterize how caseum affects antibiotic dis-
tribution, there have been a number of studies that image the 
distribution of antibiotics in granulomas and quantify antibiotic 
molecular binding to caseum.130,132,133 Pienaar et al134 have utilized 
MALDI- MS images and experimentally determined temporal gran-
uloma antibiotic concentration measurements to compare efficacy 
of tuberculosis therapy with 3 different fluoroquinolones: moxiflox-
acin, levofloxacin, and gatifloxacin. The 3 fluoroquinolones display 
different distribution patterns in granulomas that GranSim can reca-
pitulate. These simulations show moxifloxacin has a slight advantage 
in sterilizing granulomas over the other 2 fluoroquinolones. This is 
likely due to higher intracellular accumulation of moxifloxacin, allow-
ing it to better target intracellular bacterial populations and eliminate 
the population of infected macrophages. This reduction in infected 
macrophages causes treatment with moxifloxacin to reduce the 
predicted number of activated macrophages and TNF/IL10 ratios in 
granulomas more than treatment with gatifloxacin and levofloxacin. 
Because infection, immune response, and treatment are modeled to-
gether, this provides a unique opportunity to study how antibiotics 
assist the immune system in sterilizing granulomas, as well as how 
they indirectly modulate the balance of immune responses over the 
course of therapy.
Because active TB can be considered an immune response that 
is out of balance—too little pro- inflammatory mediators, or too many 
anti- inflammatory mediators, another approach to treatment is to 
modify the levels of 1 or both of the pro- and anti- inflammatory re-
sponses to achieve latency. The same idea could also be considered 
for clinically latent TB, though the idea would be to tip the distribu-
tion slightly toward pro- inflammatory responses and thus eliminate 
Mtb without inducing additional inflammation. These approaches, 
generally termed host- directed therapies, might be considered sepa-
rately or in combination with antibiotic treatment.135 One theory for 
how combining antibiotics and host- directed therapy is beneficial is 
that these therapies can modulate the inflammatory balance and re-
duce recruitment of immune cells to a granuloma, resulting in smaller 
lesions and thus better penetration of antibiotics into lesion. Another 
theory is that many bacteria in granulomas are non- replicating and 
less susceptible to antibiotics. Host- directed therapy and reduced 
immune pressure may encourage bacterial replication, making them 
more susceptible to certain antibiotics.
Host- directed therapies include TNF inhibitors such as 
Etanercept and PDE4 inhibitors. There is evidence that TNF is re-
quired for protection during Mtb infection and TNF inhibitors can 
contribute to reactivation of latent TB.136–138 Simulations at the 
cellular scale by Marino et al indicate low availability of TNF pres-
ent in granulomas due to anti- TNF therapies increases likelihood of 
reactivation.14 Additional simulations by Fallahi- Sichani et al105 in-
corporated molecular scale binding kinetics of anti- TNF molecules, 
and show that anti- TNF molecules with increased permeability and 
binding to membrane- bound TNF limit the ability to control bacte-
rial growth in granulomas. However, there have been cases where 
TNF inhibition or reduced production had some beneficial effects 
in conjunction with antibiotics in human patients co- infected with 
HIV.139,140 Additionally, murine and rabbit TB models offer evidence 
that a PDE4 inhibitor given with antibiotics leads to decreased lung 
involvement and lower bacterial loads compared to antibiotics 
alone.141–143
Because the inflammatory balance that is required to form and 
stabilize a granuloma is a complex process, it is difficult to pre-
dict how modulating this balance through the use of host- directed 
therapies will affect the granuloma and treatment outcomes. These 
potential outcomes include the percent of non- sterile granulomas 
over the course of treatment, which indicates how well treatment 
provides sterilizing activity. Other outcomes, such as average CFU 
and granuloma size over the course of treatment, show how modu-
lating the inflammatory response affects bacterial growth and the 
ability of antibiotics to penetrate the granuloma. GranSim simula-
tions exhibit immunomodulatory effects by either depleting the 
amount of TNF or IL- 10 present in the simulation, or by model-
ing the PK of anti- TNF drugs, such as Etanercept, that can bind 
and neutralize TNF molecules.14,105 Simulating these host- directed 
therapies along with the delivery of antibiotics to fully formed in 
silico granulomas shows a reduction in granuloma size compared 
to antibiotics alone (Figure 7). However, the host- directed ther-
apies with antibiotics tend to have longer sterilization times and 
greater treatment failure rates compared to just antibiotics, sug-
gesting that host- directed therapies may not be beneficial in treat-
ing human granulomas. The median CFU is higher in granulomas 
treated with host- directed therapies and antibiotics compared to 
antibiotics alone after about 10 to 20 days of treatment. By com-
parison, host- directed therapies start to reduce granuloma sizes 
between 30 and 50 days. Because host- directed therapies reduce 
the amount of TNF present, they inhibit macrophage activation 
and ability to control Mtb growth. The timescale over which the 
host- directed therapies produce potential benefits such as reduc-
ing granuloma size for better antibiotic penetration is longer than 
the timescale over which disrupting the balance of cytokines leads 
to granulomas with more bacteria. Thus, these simulations predict 
that modulating this inflammatory balance through the use of host- 
directed therapies in conjunction with antibiotics to reduce cellular 
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recruitment and granuloma size may not provide any benefits over 
antibiotics alone.
11  | THE CONCEPT OF BAL ANCE IN 
OTHER DISE A SES
The importance of a balanced immune response to promote path-
ogen clearance and maintain host protection is evident in a wide 
range of infections. To demonstrate the way in which balance has 
been highlighted more generally, we considered a range of other 
diseases including Leishmania (granulomatous), H. Pylori (persistent) 
infection, sepsis (acute), and HCV (viral).
11.1 | Leishmania
Another persistent infection that likely requires balance to achieve 
control is Leishmania. Leishmania is a parasite that causes disease 
manifestation in the skin or internal organs, including the spleen 
and bone marrow.144 Macrophages are the primary host cells for 
Leishmania; however, it is possible for the parasite to inhabit neutro-
phils, fibroblasts, and DCs.145
During progressive infection, cytokines play different roles in 
containment of Leishmania infection.146 In general, parasite growth is 
dependent on IFN- γ, as well as other inflammatory cytokines. IL- 12, 
TNF, IFN- γ are usually associated with parasite clearance,147,148 while 
IL- 4, IL- 10, IL- 13, and TGF- β are often associated with a dampened 
F IGURE  7 Effects of host- directed therapies on treatment outcome. (A) An in silico biorepository of 232 granulomas was created using 
GranSim and an infection period of 200 days. Starting at day 200, different treatments were simulated for 180 days: antibiotics alone 
(gray), antibiotics with varying doses of etanercept (500 μg/kg in red, 250 μg/kg in orange, 100 μg/kg in yellow), antibiotics with a 20% 
TNF- depletion (green), and antibiotics with 20% TNF- depletion and 10% IL- 10 promotion (blue). Percent depletions and promotions were 
simulated by reducing or increasing the amount of cytokine secreted from immune cells compared to a baseline simulation. (B) The percent 
of granulomas that contain bacteria over the course of treatment shows that antibiotics alone sterilize more granulomas and sterilize faster 
than any of the host- directed therapies. (C) Host- directed therapies tend to have higher median CFU compared to antibiotics alone from 
10- 20 days post- treatment and later. (D) Simulations involving host- directed therapies result in granulomas that gradually decrease in size, 
compared to those involving only antibiotics (only medians shown)
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immune response and persistence of the parasite.149 As infection 
advances, granulomas begin to form.150 It was assumed that these 
were non- necrotizing; however, a recent study found almost 20% 
of cutaneous leishmaniasis contained caseated granulomas,151 high-
lighting the need to again understand the dynamic balance of pro- 
and anti- inflammatory immune responses to this infection.
One of the first models to look at cytokine- related activities in 
Leishmania infection152 focused on a TH1/TH2 paradigm, using these 
as proxies for inflammatory cytokines (TH1) and anti- inflammatory 
cytokines (TH2). The model predicted that stable solutions existed 
in 2 situations: (i) TH1 response overtakes TH2, resulting in a per-
sistent, active infection; (ii) A balance between TH1/TH2 is reached, 
resulting in an asymptomatic infection. It was also observed that 
TH1 was required to be dominant to remove the parasite and that 
Leishmania exploits the TH2 response to its benefit.
In recent Leishmania models, cytokines have been modeled 
more explicitly. Siewe et al153 used an ODE model to explore im-
mune response to L. donovani using pro- and anti- inflammatory (M1 
and M2) macrophages, DCs, T cells, parasites, and concentrations 
of cytokines. Through the observation that IFN- γ greatly reduced 
Leishmania infection, the authors perform simulations for treatment 
with sodium antimony gluconate (SAG), which enhances T- cell pro-
liferation and response. When looking at the efficacy of treatment, 
they find that a fixed total amount of drug, given intermittently, was 
not as effective as continuous treatment. During continuous treat-
ment, an optimal window of time to start SAG was seen 3- 10 days 
post infection, to reduce parasite burden: if started too early, then 
the immune system likely has insufficient time to be alerted; starting 
too late allows the parasite load to grow quickly, which diminishes 
drug effects. Thus, not only should timing be considered in treat-
ment but it should also be considered part of the dynamic balance of 
the immune system in response to the pathogen.
Some groups have taken interest in specific cytokines and their 
production sources in Leishmania infection. Albergante et al154 used 
a Petri net model to look at how source of IL- 10 impacts L. dono-
vani parasite burden in granulomas. Inhibiting CD4+ IFN+ Th1 and 
NK cells from producing IL- 10 results in no reduction in peak par-
asite burden, but does lead to delayed clearance of the parasites. 
Inhibiting myeloid cells from IL- 10 production results in a reduced 
peak burden and faster clearance of the parasites, but increases the 
amount of pro- inflammatory cytokines, and therefore, host damage. 
This further supports the idea that cell secretion of pro- and anti- 
inflammatory mediators helps create a trade- off between reducing 
tissue damage and simultaneously controlling pathogen levels.
Investigating how the balance among cytokines affects the host 
in Leishmania infection in the longer term has only recently been ex-
plored.155 Using a cellular automata/lattice- gas model, Ribeiro et al. 
incorporates TH cells, cytokines, and adenosine inhibition of T cells 
to study host lesion size for several species of Leishmania. In simula-
tions, they find that using sufficient levels of Adenosine to inhibit T 
cells in the range of 0%- 20% had little effect on the maximum lesion 
size. When inhibition of T cells increased from 20% to 40%, an in-
crease is seen in host lesion size. Higher inhibition of T cells results 
in decreased host lesion size. The group also finds that a T- cell inhibi-
tion range of 0- 15% represents the peak of a lesion that could even-
tually heal, while anything above 20% disrupts the balance to such 
an extent that lesions would not heal and would continue to grow. 
The model implicates that both cells and cytokines play a key role 
in balance. Strong inhibition from 40% to 100% results in reduced 
lesions, but with high parasite burden. Weak T- cell inhibition results 
in better containment of parasites, but more host damage. This ap-
peared worst with intermediate inhibition from 20% to 40%, where 
there is enough of a host response to cause damage, but the parasite 
is never fully contained, which results in growing lesion size. Further 
work should extend this idea to look at the balancing of specific cy-
tokines in Leishmania infection to predict if a dynamically optimized 
trade- off can reduce host damage during immune response while 
clearing the parasite.
11.2 | H. pylori
Helicobacter pylori is a bacterial pathogen that colonizes the intestinal 
tract of humans. It is estimated that up to 50% of the global popula-
tion is infected with the bacterium, and as high as 70% in Africa.156 In 
general, people infected with H. pylori are asymptomatic and there is 
some evidence that this bacterium confers a benefit to its host. It has 
been suggested that H. pylori can protect against Mtb infection,157 as 
well as other diseases including gastroesophageal reflux disease,158 
inflammatory bowel disease (IBD),159 and allergic conditions such as 
asthma.160 However, these findings are often linked to the so- called 
hygiene hypothesis,161 and H. pylori is more commonly implicated in 
causing conditions such as persistent gastric inflammation, peptic 
ulcers, and gastric cancer.162–164
Helicobacter pylori colonizes the stomach, where there is very 
little microbial competition,165 and deploys a range of adaptive 
mechanisms to make clearance by the immune system difficult, 
despite all infected individuals mounting an immune response to 
the bacteria. In the asymptomatic cases, this immune response, 
while detectable, is not detrimental to health, and the bacteria and 
host reach a symbiotic equilibrium.166 The balance between pro- 
and anti- inflammatory cytokines in the gut following infection 
with H. pylori has been suggested to be important in determining 
the severity of symptoms.167 Infection with H. pylori in humans 
stimulates the infiltration of lymphocytes and monocytes along 
with significantly increased expression of IL- 1, IL- 8, and IL- 6 in the 
gut by 2 weeks post infection,166 and persistent infection is asso-
ciated with increased expression of additional cytokines, including 
IFN- γ, TNF, and IL- 10.168 The T- cell response to H. pylori is primar-
ily driven by Th1, Th17, and Treg cells.
Kirschner and Blaser previously developed models describing 
the steady- state dynamics of H. pylori colonization depending on 
nutrient availability, involving an auto- regulatory network in which 
inflammation leads to nutrient release.169,170 Through these models, 
they demonstrate that downregulation of the host immune response 
can be beneficial to the host in the presence of microbial evasion 
strategies against the immune response, as is the case with H. pylori 
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in humans.170 In this case, the appropriate immune response requires 
a balance to be reached consisting of an inflammatory response that 
is necessary for microbe control, and negative feedback to ensure 
the response is not overly harmful to the host.171 In particular, it 
has been shown that downregulation of regulatory T- cell function 
is associated with the development of life threatening peptic ulcers 
in humans infected with H. pylori.172 This result has been echoed in 
mice where IL- 10 has been demonstrated to be essential for prevent-
ing H. pylori induced gastritis in Rag2−/− mice. It has also been shown 
that downregulated inflammatory responses are associated with re-
duced gastritis in children.173 The role of pro- and anti- inflammatory 
cytokines in H. pylori is thoroughly reviewed in.174
Other models have focused on the role of CD4+ T cells in H. py-
lori infection using a system of ODEs to determine how IL- 21, a 
pro- inflammatory T cell- derived cytokine, maintains a persistent 
pro- inflammatory T- cell immune response driving chronic gastritis 
during H. pylori infection.175 The authors also extended this model 
to an ABM that was used to demonstrate that there is a crucial con-
tribution of Th1 and Th17 effector responses as mediators of his-
topathological changes in the gastric mucosa during chronic stages 
of infection.176 These results have also been verified in mice and 
demonstrate that a balance of different inflammatory mediators is 
required to achieve an appropriate response in this disease.
11.3 | Sepsis
Sepsis is an acute systemic inflammatory response to an infec-
tion and is the major cause of death among critically ill patients 
in the developed world. The most common causes of sepsis are 
Staphylococcus aureus and Escherichia coli, although there are many 
other bacteria capable of causing the condition.177 Sepsis is charac-
terized by a systemic pro- inflammatory response178 and occurs due 
to an imbalance of pro- and anti- inflammatory cytokines following 
dysregulation of an initial, appropriate host response to infection. In 
contrast to the other infections discussed herein, a sepsis response 
primarily involves the innate immune pathway that still utilizes both 
pro- and anti- inflammatory mediators179,180 and occurs on a rapid 
timescale, and thus is not a persistent infection. The fast timing of 
immune dysregulation in sepsis makes clinical and experimental 
studies on disease development difficult to perform, thus in silico 
studies are important to provide insight into the early immune re-
sponse in sepsis.
Several immune models have been developed to study sep-
sis and focus on the role of cytokines in the immune response 
(reviewed in181). Yang et al182 showed that the outcome of sepsis 
progression is improved when IL- 10 is increased early in infection. 
Conversely, An et al183 calibrated their previously published Innate 
Immune Response ABM (IIRABM) to achieve sepsis dynamics and 
proposed several schemes for intervention that suggested that TNF 
inhibition almost always contributed to resolution, and inhibition 
of anti- inflammatory cytokines GCSF and IL- 10 also improved out-
come. These conflicting results could be a result of the time frame 
under study as the mathematical model by183 only considered early 
inflammatory events (up to 7 days), whereas work by Yang et al182 
considered a longer time period of 41 days; however, taken together 
they highlight the important role of immune balance in controlling 
infection.
The importance of restoring balance for recovery from sep-
sis has also been highlighted by a number of in vivo and in vitro 
studies.184–188 It has been suggested that inflammatory and anti- 
inflammatory responses involving both the innate and adaptive im-
mune systems are each equally important and represent potential 
targets for immune therapy to improve sepsis outcomes.184–188 Luan 
et al189 observed that in a murine model of sepsis, inhibiting TGF- β 
could improve host outcome by reducing immunosuppression. It has 
also been shown that the important mechanisms in pathology alter 
over the course of infection, with pro- inflammatory cells and cyto-
kines playing a major role in pathogenesis early in infection, but high 
levels of immunosuppression by anti- inflammatory cells and cyto-
kines responsible for worsening outcomes if the initial inflammatory 
phase is survived.190
11.4 | Hepatitis C
The role of balance in immunity has also been highlighted in the field 
of virology. Here we present a case study exploring the immune re-
sponse to hepatitis C virus (HCV) infection. HCV infection is chronic, 
and it is estimated that up to 170 million individuals are infected 
worldwide.191 Due to shared transmission routes, co- infection with 
HIV is common: approximately 16% of HIV positive individuals in the 
United States and Europe are also infected with HCV.192
HCV infects the hepatocytes in the liver where it continually 
replicates, establishing an intrahepatic infection.193 The innate im-
mune response to HCV involves the production of interferons and 
cytokines, and the recruitment of natural killer (NK) cells.194 This 
phase of the immune response is thought to be critical in determin-
ing the outcome of an infection; however, high numbers of NK cells 
are also associated with tissue injury.195,196 The subsequent adaptive 
response requires myeloid cells such as DCs, and macrophages, as 
well as T and B cells.
The main inflammatory mediator of HCV infection is IFN- γ, pro-
duced primarily by NK and NK T cells. IFN- γ stimulates the produc-
tion of TNF by Kupffer cells (KCs).197 The inflammatory response is 
essential for viral clearance; however, in hosts where clearance is 
not achieved, this response is damaging. Regulatory T cells are im-
portant in controlling the balance between host damage and viral 
control and are induced following galectin- 9 production by KCs.198 
Alternatively, Tregs have also been associated with inducing chronic 
infection199 and the virus itself can use this pathway to promote im-
mune tolerance.200 Thorough reviews of the immune response to 
HCV response are available for more details.201,202
Much of the modeling work on HCV infection focuses on viral 
kinetics and uses target- cell- limited models to determine the ef-
fect that the immune response may have on controlling the virus 
in the presence of HIV co- infection and does not specially exam-
ine the role of pro- and anti- inflammatory cells and mediators in 
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HCV infection.203,204 There are still open questions related to the 
concept of balance in HCV infection and the role of pro- and anti- 
inflammatory cells in infection outcomes that lead to a chronic, yet 
stable latent infection. Clinical studies that seek to identify signif-
icant differences in cytokine profiles between those that do and 
do not clear or control virus have had limited success in identifying 
influential cytokines.205 Modeling and simulation could be a power-
ful tool in understanding the role that pro- and anti- inflammatory 
mediators play in controlling HCV infection and answering some of 
these questions. Based on similarities with other persistent infec-
tions discussed herein, we hypothesize that a similar trade- off exists 
for HCV as well.
12  | DISCUSSION
The concept of a dynamically achieved, spatially dependent steady 
state is ubiquitous in biology. Nature has numerous ways to self- 
regulate and respond to novel or pathologic perturbations, whether 
localized or systemic; natural systems, such as predator- prey sys-
tems or regulation of gene expression, often rely on dynamic ad-
justments over varying timescales to attain and maintain this sort of 
balance. It is not surprising, then, that the immune system operates 
on a similar level of complexity. During infection, the immune system 
mounts inflammatory responses to neutralize or kill pathogens, but 
this response can also damage host cells, leading to a trade- off be-
tween clearing the pathogen and limiting damage to host tissues. In 
this review, we present examples where the immune response seeks 
an optimized dynamic balance with a pathogen that fails to be elimi-
nated, and we explore the role of pro- and anti- inflammatory signals 
that participate in this process.
The Goldilocks principle (named from the children’s story) re-
fers to responses that are “just right” (ie, not too strong and not too 
weak).5,206,207 This is a paradigm that is repeated in many instances 
(from intracellular signaling to porridge) and is closely related to the 
concept of balance. Recent authors suggested that the Goldilocks 
principle implies that “…immunity must be choreographed so that in-
vaders are purged quickly, inflammation tempered, and homeostasis 
preserved,” which is consistent with our hypotheses.206 It should also 
be noted that balanced immune responses are not split evenly be-
tween pro- and anti- inflammatory mediators, but instead are dynamic 
and vary with respect to each other over the course of infection.
Recent work similarly highlights the importance of balanced pro- 
and anti- inflammatory responses in combating Mtb infection and ex-
tends this concept to spatial and temporal dimensions. These studies 
also indicate that a better understanding of this aspect of immunity 
could improve vaccine development and drug treatment.5,208,209 
Cytokines embody both good and bad roles in TB, because they can 
have context- dependent protective and pathologic consequences.5 
Monin and Khader208 similarly suggested that chemokine responses 
can be both good and bad, and that protection in TB is a trade- off 
between immune control and bacterial replication mediated by ap-
propriately calibrated responses. Our review offers a unique and 
detailed look at the role of pro- and anti- inflammatory balance by 
consolidating insights from experimental studies and mathematical 
models that incorporate the complex, multi- scale interactions in-
volved in host- pathogen dynamics.
We have considered specific cells and cytokines to be either 
pro- or anti- inflammatory based on functions that are widely ac-
cepted in both in vivo and in vitro studies. It is worth noting that 
our strict classifications of cells and cytokines into either pro- or 
anti- inflammatory categories may be too simplistic. There are many 
examples showing that cytokine amount, cell or target cell nature, 
activating signal cascade, timing, sequence of cytokine action, and 
even the experimental study system can all greatly influence cy-
tokine properties.210,211 This is demonstrated by plasticity within 
some T- cell subsets, whereby cells can switch from pro- or anti- 
inflammatory profiles, or in the case of multifunctional T cells, simul-
taneously express cytokines with different properties.65-72
In addition to its dynamic nature, inflammatory balance is some-
thing that is maintained over various time and length scales. To 
mount an appropriate immune response during an infection, balance 
is achieved at the molecular scale by signaling appropriately and in-
ducing proliferative responses within immune cells, which in turn in-
fluence tissue- scale behaviors that influence organ- level responses 
and host- level outcomes. These processes are occurring over time 
scales ranging from seconds to years and spatial scales ranging from 
sub- micron to meters. While the relationship between these scales 
are difficult to study in a traditional wet lab setting, mathematical 
and computational modeling can be used to integrate data from 
these multi- scale interactions and outcomes. Modeling these inte-
grated responses over space and time allows the fullest picture of 
the dynamics of balance, and enables us to make predictions that 
can have the greatest impact on disease outcomes. In addition, com-
putational modeling is a vital tool to isolate and understand factors 
from the larger integrated model that regulate such complex biolog-
ical systems.
While we now better understand how a balance of pro- and anti- 
inflammatory mediators may be required for control infection, we 
have not yet fully utilized that concept for therapeutic development. 
Experimentally driven mathematical modeling will allow us to iden-
tify how antibiotics or host- directed therapies can be used to modu-
late inflammatory balance and promote sterilizing immunity against 
pathogens or tilt host- pathogen interactions in favor of the host.
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